A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

NCT02864199 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

Hoffmann-La Roche